Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
The purpose of this study is that ruxolitinib may be a possible treatment option for relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.
Relapsed or Refractory Hodgkin Lymphoma|Primary Mediastinal Large B-cell Lymphoma
DRUG: Ruxolitinib
To assess the efficacy of disease control including complete response (CR), partial response (PR) and stable disease (SD), From date of enrollment until the date first documented disease progression or unacceptable toxicity, whichever came first, assessed up to 48months
Toxicity profile, CTCAE v4 (Common Terminology Criteria for Adverse Events v4.0) In the present study, toxicities will be recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (CTCAE), version 4.0. The full CTCAE documentation is available on the NCI web site, at the following address: http://ctep.cancer.gov/forms/CTCAEv4.pdf The occurrence of severe adverse event (SAE) should be also reported to the Novartis Safety Office within 24 hours., from the date of informed consent signature to 30days after last drug administration|Overal Survival, from the date of first drug administration until the date of death, assessed up to 48months
Patients will take ruxolitinib 20 mg orally twice a day, 40mg in total per day, for 4 weeks.4 weeks is 1 cycle. Treatment will be continued until documented disease progression or unacceptable toxicity and the maximum period of treatment is 16 cycles.